Link to publication in ResearchOnline Citation for published version (Harvard): Frankis, J, Flowers, P, McDaid, L & Bourne, A 2018, 'Low levels of chemsex among men who have sex with men, but high levels of risk among men who engage in chemsex: analysis of a cross-sectional online survey across four countries', Sexual Health, vol. 15, no. 2. https://doi.Abstract. Aim: This paper establishes the prevalence of chemsex drug use amongst men who have sex with men (MSM), the extent to which these drugs are used in a sexual context, as well as their associated behaviours and circumstances of use. Methods: Data from a cross-sectional, online survey of 2428 MSM recruited via gay sociosexual media in Scotland, Wales, Northern Ireland and the Republic of Ireland were analysed. Results: Whilst almost half (48.8%) of participants had ever taken illicit drugs, lifetime chemsex drug use was less common (18.0%) and far fewer reported chemsex drug use in the last year (8.2%) or last 4 weeks (3.0%). One quarter (27.1%) of men who used chemsex drugs in the last year reported no sexualized drug use, but almost three-quarters (72.9%) did. Only 6.1% of the whole sample reported sexualized chemsex drug use in the last year. The odds of reporting chemsex in the last year were significantly higher for men aged 36-45 (AOR = 1.96), single men (AOR = 1.83), men who were HIV positive (AOR = 4.01), men who report high risk sex (AOR = 4.46), being fisted (AOR = 7.77), or sex in exchange for goods other than money (AOR = 4.7) in the last year and men who reported an HIV test in the last 3 months (AOR = 1.53). Discussion: Only a small proportion of MSM in these four countries reported chemsex, and, for the first time, we demonstrate that not all chemsex drug use was sexualized.
Introduction
'Chemsex', the use of drugs in sexual settings amongst men who have sex with men (MSM), has received sustained attention in the United Kingdom (UK) for the last five years. Chemsex in this geographic context is typically associated with the use of mephedrone, crystal methamphetamine, ketamine and/or gamma-hydroxybutrate (GHB) or the pre-drug gammabutyrolactone (GBL) (Stuart, 2013; Kirby & Thornber-Dunwell, 2012) . Qualitative research from London highlights a range of psychological, social and relational harms associated with chemsex, as well as a propensity for overdose (Bourne et al., 2015a) . Indeed, data from the coroner of England & Wales indicates a 119% rise in GHB/GBL overdose related deaths between 2014 and 2015, with an individual dying every 12 days, is potentially linked to chemsex (Hockenhull et al., 2016) .
Further to this, sexual health harms have been widely examined, with several clinic-based studies indicating an increased likelihood of having been diagnosed with a sexually transmitted infection (STI) within the previous 6 or 12 months among those who had used one or more of the drugs associated with chemsex (Sewell et al., 2017; Ottaway et al., 2016) . Commonly reported effects of these drugs include heightened sexual arousal, increased longevity of sex and, as a consequence, an increased potential for higher number of sexual partners (Bourne et al., 2015b) .
Several studies have found illicit drug use, especially crystal methamphetamine use, to be associated with unprotected anal intercourse at both the individual (Bolding et al., 2006) and event levels . However, not all studies report this finding and care must be taken in assuming causal pathways (Prestage et al., 2007; Melendez-Torres & Bourne, 2016) . With a significant proportion of men engaging in chemsex already living with diagnosed HIV, and who largely report anti-retroviral therapy adherence Schmidt et al., 2016) , the potential for HIV transmission within chemsex environments is less certain, but still possible. In addition, the potential for toxic drug interactions to negatively impact HIV clinical outcomes is emerging and multifaceted (Garin et al., 2017) .
Despite sustained media interest in the topic (Strudwick et al., 2016; New Scientist, 2017) , there are limited data to inform estimates on the prevalence of chemsex among men who have sex with men anywhere in the British Isles, and little quantitative data to inform understandings of associated sexual behaviours. Such estimates are critically important for planning services (e.g. specialised interventions for harm reduction) and allocating resources where they are needed most (e.g. chemsex intervention v. partner notification work). While there have been a variety of papers describing findings from clinical audits or involving clinical samples (Scrivner et al., 2013; Daskalopoulou et al., 2014; Hegazi et al., 2016) , these may recruit a disproportionate proportion of men engaging in riskier behaviours and who recognise a need for health care engagement. An exception within the British Isles context comes in the Gay Men's Sex Survey , which reports overall prevalence of chemsex among MSM living in England (but does not include the other countries within the British Isles) of 6.6%. However, this measure accounts for all contexts in which these drugs are used and does not specifically indicate whether they were used in a sexual context. This paper aims to establish prevalence of the use of drugs associated with chemsex, and for the first time, the extent to which they are actually used in a sexual context, as well as determine the associated behaviours and circumstances of use. Such data will be of use to those planning service provision, those designing and delivering sexual health promotion and harm reduction interventions in diverse settings. With no data from the last five years focusing on countries or nations of the British Isles other than England, here we focus on gay, bisexual and other MSM living in Scotland, Wales, Northern Ireland (NI) and the Republic of Ireland (RoI).
Methods

Population, sampling and recruitment
The Social Media, MSM and Sexual and Holistic Health (SMMASH2) survey collected anonymous, self-complete questionnaires from men recruited online via gay-specific sociosexual media websites (Gaydar, Recon and Squirt) and smartphone apps (Gaydar, Recon, Grindr, Growlr and Hornet) between April and June 2016. All members of these sociosexual media whose i) profile location, ii) computer IP address or iii) smartphone GPS coordinates were located in Scotland, Wales, NI or RoI, were invited to participate as follows; each profile was sent two message blasts (either as a pop-up message [Gaydar, Recon, Grindr, Growlr and Squirt] or an inbox message [Hornet]) asking them to participate in our survey. In addition, banner advertisements, designed to fit the character of each website/app, were employed to advertise the survey on Gaydar, Recon, Grindr, Growlr, Hornet and Squirt. Clicking on the message blast or banner ad took participants to our survey landing page, which provided full details of the survey, highlighting they were under no obligation to take part and that participation was taken as evidence of consent. No financial incentive was given and participants were asked not to complete the questionnaire if they had already done so, but duplicates were not screened for.
Fraudulent and partial entries were screened and deleted. Participants were provided with details of local sexual and mental health services online upon survey completion or exit. Each site/app has a minimum user age of 18, but some men aged 16-17 did participate. In total, 3217 men completed useable questionnaires.
Survey content
Questionnaires surveyed demographics (age, ethnicity, sexual orientation, educational qualifications, relationship status and financial worries), sexual health indicators (HIV testing and status), commercial sex experience and various sexual behaviours in the previous 12 months. A measure of condomless anal intercourse (CAI) with higher risk for HIV infection was derived to include men who reported CAI with ≥ 2, casual, and/or HIV status unknown/serodiscordant partners in the previous 12 months (compared with men reporting CAI with 0/1, regular and/or HIV status known/seroconcordant partners only). These measures were developed and used previously in the MRC Gay Men's Sexual Health Survey and SMMASH study (Frankis et al., 2016) . Participants were also asked questions about their use of illicit drugs (adapted from EMIS; Schmidt et al., 2016) , including lifetime experience of illicit drug use (defined here as 'e.g. cannabis, ecstasy, cocaine etc.') and when they last used crystal methamphetamine, mephedrone, GHB/GBL and ketamine respectively, the main 4 chemsex drugs (known colloquially as 'chems'). Men who reported chemsex drug use in the last year, were also asked, 'In the last 12 months, how much of the sex you've had was after taking [drug]' for each of these 4 chemsex drugs, with responses on a 7 point likert scale ranging from 'None of it' to 'All of it'.
Ethical approval was granted by Glasgow Caledonian University School of Health and Life
Sciences Ethics Subcommittee (HLS id: HLS/NCH/15/26) and consent assumed by survey participation.
Analyses
Quantitative data were analysed with IBM SPSS 23 for Mac by the first author. Only men who answered questions about their lifetime drug use were included in this analysis (n = 2428), of whom half (51.2%, n = 1193) had never taken illicit drugs and half (48.8%, n = 1135) had. Chisquare tests and univariate logistic regression were used for bivariate comparisons. Variables significant at the bivariate level (P < 0.05) were entered into a multivariate logistic regression model to estimate the adjusted odds ratios (AOR) and 95% confidence intervals (CI) for reporting chemsex in the last year. Here we define 'chemsex' as reporting having at least some sex after taking a chemsex drug (crystal methamphetamine, mephedrone, GHB/GBL or ketamine) in the last year.
Results
Sample demographics, sexual behaviours and HIV testing
The characteristics of survey participants are shown in Table 1 . Almost half of participants were recruited in Scotland, one quarter in RoI, with fewer in Wales and NI. The mean age of participants was 41 years (range 16-78, sd = 13.5), 97.3% were white and whilst most (81.9%)
were gay identified, one in six were bisexual (17.2%) and several identified as straight (0.7%) or 'other' (0.2%). Around 1 in 20 (5.7%) identified as transgender. Almost two-thirds (62.7%) had a degree or postgraduate level education. Over half (61.1%) were single, but 29.7% had a regular male partner (including same sex marriage and civil partnerships) and 9.2% had a regular female partner (including opposite sex marriage). Just under half (42.4%) said they had financial worries (sometimes, most, or all of the time). Most (82.3%) said they used the commercial gay scene (i.e. gay bars, clubs and saunas) once a month or less, with over half (51.4%) saying they never did.
Overall, 92.0% were either HIV negative or untested, and 8.0% said they had tested HIV positive.
Just over one third (36.2%) report high risk CAI, 6.7% said they had been fisted and 29.6% had attended a sex party / had group sex in the last year, respectively. A small proportion of men reported sex in return for money (2.4%) or 'anything else' (1.5%) in the last year. Half (50.5%) reported an HIV test in the last year and almost one quarter (22.2%) reported an HIV test in the last 3 months. 
Illicit Drug use amongst MSM; individual and event level analysis
Participants' illicit drug use is shown in Table 2 . Whilst almost half of participants had taken any illicit drugs in their lifetime (e.g. cannabis, ecstasy, cocaine etc.), lifetime chemsex drug use was far less common (crystal methamphetamine 5.1%; mephedrone 9%; GHB/GBL 10%; ketamine 11.5%) and fewer still reported using these drugs within the last year (crystal methamphetamine 2.5%; mephedrone 4.5%; GHB/GBL 4.9%; ketamine 3.8%). Only a small proportion of men (≤ 2% per drug) reported using any of these chemsex drugs in the last 4 weeks.
In concert, whilst 18% (n = 435) of participants had used any chemsex drugs in their lifetime, only 8.2% (n = 198) had used them in the last year and just 3.0% (n = 72) had used them in the last 4 weeks.
In relation to event based sexualized drug use, we assessed the proportion of sexual events that incorporated the use of chemsex drugs. We asked those men who reported use of each chemsex drug in the last year what proportion of the sex they had had was after taking each drug, respectively. Combining these measures we found that of the 198 men who report any chemsex drug use in the last year, one quarter (27.1%, n = 55) reported no sex on chemsex drugs, almost half (46.2%, n = 91) said less than half of their sex was after taking chemsex drugs and one quarter (25.9%, n = 51) said that half or more of their sex was after taking chemsex drugs. Thus for the whole sample of men in this study, 6.1% reported chemsex and 93.9% reported no chemsex in the last year. Stratifying this further, for the whole sample, most participants reported no chemsex drug use in the last year (91.7%, n = 2186), 2.3% (n = 55) reported non-sexual chemsex drug use only, 3.8% (n = 91) said that less than half of their sex was chemsex and 2.1% (n = 51) said that most of their sex was chemsex. Finally, a small proportion of men reported 'slamming' (injecting drugs themselves or by another person) chemsex drugs at sex parties in the last year (n = 30, 1.3%); although this represents 21% of those men who reported any chemsex in the last year. 
Characteristics of men who report chemsex in the last year
We examined the characteristics of men who do and do not report chemsex in the last year (see Table 3 ). When controlling for the factors significant at the bivariate level in the multivariate regression analysis 1 , the adjusted odds of the likelihood of reporting chemsex in the last year were significantly higher for men aged 36-45 compared to 46+ (AOR = 1.96), single men (AOR = 1.83), men who report high risk CAI (AOR = 4.46), men who said they were fisted in the last year (AOR = 7.77), men who reported sex in exchange for goods other than money (e.g.
cigarettes, drugs, food etc.) (AOR = 4.7), men who were HIV positive (AOR = 4.01) and men who reported an HIV test in the last 3 months (AOR = 1.53). 
Discussion
This is the first study of chemsex across Scotland, Wales, NI and RoI, and the first therein to distinguish chemsex drug use per se from its specific use within sexual contexts. Within this online sample of MSM, we have demonstrated the low prevalence of chemsex drug use overall (8.2% within the previous 12 months), in contrast to the relatively high levels of illicit drug use at the individual level. Our study also indicates that not all chemsex drug use occurs within a sexual context, as more than a quarter (27.1%) of those who had used chemsex drugs reported no sex while under their influence. However, a quarter (25.9%) of those who had used chemsex drugs said that the majority of their sex occurred after taking them. Our findings clearly demonstrate that the use of drugs associated with chemsex is a minority behaviour across the UK, supporting research in England , but expands our awareness of the proportion of sex that is had under their influence.
While our findings suggest around one in seventeen (6.1%) MSM have engaged in chemsex within the last year, these men were more likely to be aged 36-45, single, report high risk CAI, report being fisted, report group sex, exchanging sex for non-financial benefits (e.g. cigarettes, drugs, food etc.) and an HIV positive status, providing clear targeting for intervention. It is also essential to acknowledge that while there may be a relatively low population prevalence of chemsex in the British Isles as a whole, it is likely that this behaviour is geographically concentrated in large gay urban centers (e.g. Brighton, Manchester, London; Schmidt et al., 2016) . These high levels of associated risk taking and inequalities suggest the importance of early identification of those who may be most vulnerable to chemsex-related harm and the need to develop a specialised responsive patient pathway to address the specific needs of those who may benefit most from intervention. Our findings also suggest many of these men were already in touch with services, because of their HIV care or recent HIV testing history, meaning that existing sexual health services represent a suitable conduit for timely intervention.
With regard to future intervention development, the findings here highlight several opportunities for further focused research. It is important to learn about those salutogenic factors, or assets, that enable most of men who engage with illicit drugs to avoid problematic drug use.
Equally, for those who reported lifetime-use of chemsex drugs, understanding how they have maintained and managed episodic or one-off use, rather than continuous or repeated use, may inform interventions for problematic drug use. A thorough consideration of the pathways in and out of illicit drug use and sexualized drug use in particular may benefit the provision of culturally appropriate guidance for the wider MSM population. (Prah et al., 2016) . That said, 83.2% of men in this sample reported using the commercial gay scene once a month or less, suggesting a minimal overlap with a venue-based study. It was not possible to calculate a response rate for these data, given the nature of online surveys and men's use of multiple sites/profiles. However, the demographic profile and sexual behaviours of the sample achieved herein was comparable to other surveys of MSM (e.g. , which supports the wider generalizability of these data. A clear limitation is that our results rely on estimates of self-reported behaviours, spanning the previous year, rather than any objective measure of behaviour. Moreover, we are relying on recall of drug-taking behaviours, which may themselves impact recall accuracy. Nevertheless, such self-report estimates are ubiquitous within online cross-sectional surveys and no methods to provide more objective measures are available.
Finally, our analyses and conclusions assume an at least partially causal relationship between chemsex, drug taking, sexual risk taking and demographic characteristics (which are themselves likely to be bidirectional relationships) which given the correlational nature of our cross-sectional study design must be interpreted with caution, though this generic criticism applies to much public health behavioural research.
In observing the relatively small proportion of men who engage in chemsex, it is crucial that those funding, designing and delivering sexual health interventions for gay, bisexual and other MSM also recognise their particularly acute needs (Bourne et al., 2015a) . Recognising and understanding diverse motivations for engaging in chemsex is central to helping men manage their drug use and reduce the harms to themselves or others . While not all MSM who engage in chemsex will experience difficulties, those that do require tailored harm reduction and psycho-therapeutic interventions. These should be positioned within broader programs that address syndemic health inequalities and support the holistic sexual health of gay, bisexual and other MSM, rather than focusing on singular issues or behaviours (Singer et al., 2017) .
